CeriBell (NASDAQ:CBLL) Receives “Buy” Rating from BTIG Research

CeriBell (NASDAQ:CBLL)‘s stock had its “buy” rating reaffirmed by stock analysts at BTIG Research in a research note issued on Tuesday,Benzinga reports. They currently have a $28.00 price target on the stock. BTIG Research’s price target would indicate a potential upside of 45.08% from the company’s current price.

Other analysts have also issued reports about the stock. Canaccord Genuity Group dropped their target price on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. Weiss Ratings downgraded CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, CeriBell presently has an average rating of “Moderate Buy” and an average price target of $21.80.

CeriBell Price Performance

Shares of CeriBell stock opened at $19.30 on Tuesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 10.01. CeriBell has a one year low of $10.85 and a one year high of $24.33. The business’s 50 day simple moving average is $18.55 and its two-hundred day simple moving average is $19.08. The stock has a market capitalization of $732.30 million, a P/E ratio of -11.84 and a beta of 0.81.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. Analysts forecast that CeriBell will post -1.69 EPS for the current year.

Insiders Place Their Bets

In other news, Director Joseph Michael Taylor sold 5,500 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $18.41, for a total value of $101,255.00. Following the completion of the transaction, the director owned 61,573 shares in the company, valued at $1,133,558.93. This trade represents a 8.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CTO Raymond Woo sold 1,966 shares of CeriBell stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $18.00, for a total value of $35,388.00. Following the sale, the chief technology officer owned 195,682 shares in the company, valued at $3,522,276. This represents a 0.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 300,685 shares of company stock valued at $5,935,326 over the last ninety days. 17.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On CeriBell

Several institutional investors and hedge funds have recently added to or reduced their stakes in CBLL. BlackRock Inc. purchased a new position in shares of CeriBell during the second quarter valued at approximately $37,657,000. Bank of New York Mellon Corp grew its stake in shares of CeriBell by 1,945.9% in the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after buying an additional 1,162,200 shares during the last quarter. KCM Capital Inc bought a new position in CeriBell during the 4th quarter valued at approximately $21,930,000. TimesSquare Capital Management LLC purchased a new position in CeriBell during the second quarter valued at $15,182,000. Finally, Royce & Associates LP bought a new stake in CeriBell in the fourth quarter worth $11,695,000.

CeriBell News Summary

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: The FDA granted 510(k) clearance for two AI enhancements to CeriBell’s cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction. The features are designed to help neurologists identify abnormal EEG patterns, reduce signal interference and review critical-care recordings more efficiently. The update expands the functionality of CeriBell’s existing point-of-care brain-monitoring system without requiring software downtime or installation. CeriBell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction
• Positive Sentiment: Second-quarter revenue rose to $28.1 million, exceeding the $27.28 million analyst consensus. Management maintained full-year 2026 revenue guidance of $114 million to $117 million, with the low end in line with consensus, suggesting continued demand for the company’s neurological monitoring platform. CeriBell Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Management’s earnings call highlighted the newly cleared AI tools and the company’s focus on improving clinical workflows and adoption of its point-of-care EEG system. The commercial benefit of the enhancements will depend on hospital uptake, clinical acceptance and the company’s ability to convert the technology into incremental revenue. CeriBell Q2 2026 Earnings Call Transcript
• Negative Sentiment: CeriBell reported a second-quarter loss of $0.51 per share, wider than the $0.45-$0.47 consensus range and worse than the $0.38 loss recorded a year earlier. The company remains unprofitable, increasing investor focus on operating leverage and the pace at which revenue growth can offset expenses. CeriBell Reports Q2 Loss, Tops Revenue Estimates
• Negative Sentiment: Reported insider-trading data shows 44 open-market sales and no purchases over the past six months, including sales by senior executives. While such transactions may reflect personal or equity-compensation decisions, the lack of insider buying is a potential sentiment headwind.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.